Skip to main content
. 2020 Jan 9;15(7):1266–1273. doi: 10.4103/1673-5374.272616

Figure 2.

Figure 2

Comparison of modified Rankin Scale scores between the cattle encephalon glycoside and ignotin (CEGI) group and the placebo group on days 90; (A) the rate of good outcomes/poor outcomes and (B) the degree of disability in acute cerebral infarction patients.

The efficacy analysis set was defined as the full analysis set (FAS) (CEGI group, n = 229; placebo group, n = 78) and the per-protocol set (PPS) (CEGI group, n = 218; placebo group, n = 73). The Cochran–Mantel–Haenszel chi-squared test was used to compare the rates of outcomes in the CEGI and placebo groups; the rank-sum test was used to compare the rates of disability in the CEGI and placebo groups. *P < 0.05, **P < 0.01.